In recent years, cardiogenetics has become a key component in the management of cardiomyopathies and channelopathies, reshaping diagnostic, prognostic, and therapeutic strategies for conditions characterized by substantial clinical heterogeneity and variable arrhythmic risk. However, the use of genetic testing in clini...
F. Fortuni, A. Matteucci, F. Angelini et al.· Giornale italiano di cardiol...· 0 citations
Genetic testing in hypertrophic cardiomyopathy (HCM) yields variable positivity rates. Identifying clinical predictors of positive genetic tests could improve pre-test counseling and refine expectations about diagnostic yield.
We analyzed consecutive genotyped HCM probands from a contemporary multicenter c...
F. Juvenal, F. Angelini, V. Dusi et al.· European Heart Journal· 0 citations
Vericiguat reduces cardiovascular death and heart failure (HF) hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF), but its non-invasive haemodynamic and remodelling effects in real-world practice remain incompletely characterized. We aimed to evaluate changes in non-invasive hemodynamic...
P. Bocchino, C. Carbonaro, G. Gallone et al.· American Journal of Cardiolo...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.